Abbott Laboratories (ABT) Expected to Announce Quarterly Earnings on Thursday

Abbott Laboratories (NYSE:ABT - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, July 17th. Analysts expect Abbott Laboratories to post earnings of $1.25 per share and revenue of $11.01 billion for the quarter. Abbott Laboratories has set its Q2 2025 guidance at 1.230-1.270 EPS and its FY 2025 guidance at 5.050-5.250 EPS.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.38 billion. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Abbott Laboratories Trading Up 0.3%

NYSE:ABT traded up $0.42 during trading hours on Thursday, reaching $133.64. 4,852,335 shares of the stock were exchanged, compared to its average volume of 6,156,828. The company has a market capitalization of $232.51 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 2.53 and a beta of 0.73. The company has a quick ratio of 1.27, a current ratio of 1.78 and a debt-to-equity ratio of 0.26. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The business has a 50-day moving average of $133.49 and a two-hundred day moving average of $128.72.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.77%. The ex-dividend date is Tuesday, July 15th. Abbott Laboratories's payout ratio is currently 30.61%.

Insiders Place Their Bets

In related news, Director Sally E. Blount sold 2,600 shares of the stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director owned 34,058 shares in the company, valued at $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is currently owned by company insiders.

Institutional Trading of Abbott Laboratories

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 10.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 51,719 shares of the healthcare product maker's stock after buying an additional 4,755 shares during the quarter. Brighton Jones LLC's holdings in Abbott Laboratories were worth $5,850,000 at the end of the most recent reporting period. Institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ABT shares. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Stifel Nicolaus lifted their price target on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a research report on Thursday, April 17th. Piper Sandler reiterated an "overweight" rating and set a $145.00 price target (up from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Wells Fargo & Company lifted their price target on shares of Abbott Laboratories from $136.00 to $147.00 and gave the company an "overweight" rating in a research report on Thursday, April 17th. Finally, Evercore ISI lifted their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average price target of $143.11.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.